Eli Lilly has agreed to acquire Kelonia Therapeutics for up to $7 billion, which includes a $3.25 billion upfront payment. This deal aims to enhance Lilly’s genetic medicine pipeline by adding Kelonia’s innovative in vivo CAR-T therapy, KLN-1010, currently in phase I for multiple myeloma. The acquisition addresses challenges in CAR-T therapies, offering a simpler, more scalable approach. Alongside this, Lilly has been active in expanding its portfolio through several other acquisitions in 2026, focusing on advancing its capabilities in genetic medicine and oncology.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.zacks.com/stock/news/2904633/lly-to-buy-oncology-biotech-kelonia-therapeutics-for-7-billion
